Shots:
- AstraZeneca reported long-term follow-up from the positive P-ll ACE-LY-004 study involves assessing Calquence (acalabrutinib) in adult patients with r/r MCL
- Result: @median follow up (38.1mos.) 44% of patients either remained on treatment or continued to be followed for survival; median DOR (28.6 mos.); estimated DOR rate @36 mos. (41.9%); m-PFS (22 mos.); estimated PFS rate @6mos. (37.2%); presented at ASH
- Calquence is a selective BTK inhibitor, binds BTK thereby inhibiting its activity, and is approved for CLL and SLL in the US and for CLL in the EU and several other countries globally
Click here to read full press release/ article | Ref: Businesswire | Image: Royal Haskoning
The post AstraZeneca Reports Long-Term Efficacy and Tolerability of Calquence (acalabrutinib) in P-ll ACE-LY-004 Study for MCL first appeared on PharmaShots.
